TY - JOUR
T1 - Multicenter in vitro comparison of piperacillin and nine other antibacterials against 1,629 clinical isolates
AU - Greenberg, R. N.
AU - Bowne, D. B.
AU - Gelfand, M.
AU - Sathe, S. S.
PY - 1990
Y1 - 1990
N2 - The antibacterial spectrum of activity of piperacillin was compared with that of other antibiotics against isolates of Escherichia coli, Enterobacter cloacae, Haemophilus influenzae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Pseudomonas cepacia, Pseudomonas maltophilia, Serratia marcescens, Enterococcus sp, Bacteroides fragilis, Bacteroides bivius, and Clostridium difficile, obtained from laboratories at hospitals in St. Louis, in Memphis, and in Newark, New Jersey. Of the 1,629 isolates tested, 91% were susceptible to piperacillin, 90% to mezlocillin, 87% to ticarcillin/clavulanate and imipenem, 83% to ceftazidime, 81% to cefoperazone, 80% to ciprofloxacin, 77% to ceftriaxone, 71% to aztreonam, and 51% to cefoxitin.
AB - The antibacterial spectrum of activity of piperacillin was compared with that of other antibiotics against isolates of Escherichia coli, Enterobacter cloacae, Haemophilus influenzae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Pseudomonas cepacia, Pseudomonas maltophilia, Serratia marcescens, Enterococcus sp, Bacteroides fragilis, Bacteroides bivius, and Clostridium difficile, obtained from laboratories at hospitals in St. Louis, in Memphis, and in Newark, New Jersey. Of the 1,629 isolates tested, 91% were susceptible to piperacillin, 90% to mezlocillin, 87% to ticarcillin/clavulanate and imipenem, 83% to ceftazidime, 81% to cefoperazone, 80% to ciprofloxacin, 77% to ceftriaxone, 71% to aztreonam, and 51% to cefoxitin.
UR - http://www.scopus.com/inward/record.url?scp=0025266269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025266269&partnerID=8YFLogxK
M3 - Article
C2 - 2183941
AN - SCOPUS:0025266269
SN - 0149-2918
VL - 12
SP - 61
EP - 70
JO - Clinical Therapeutics
JF - Clinical Therapeutics
IS - 1
ER -